Table III.
Distribution of cytokine genotypes in the cases and controls, The Los Angeles HCC Study
| Cytokine genotype | Number of cases | Number of controls | OR (95% CI)a | Adjusted ORb (95% CI) |
| Th1 genes | ||||
| TNFα | ||||
| GA/AA | 28 | 49 | 1.00 | 1.00 |
| GGc | 90 | 176 | 0.77 (0.44–1.35) | 0.88 (0.46–1.68) |
| IL-2 | ||||
| TT | 58 | 103 | 1.00 | 1.00 |
| TG/GGc | 58 | 115 | 0.91 (0.57–1.45) | 0.98 (0.57–1.67) |
| IL-12 | ||||
| AA | 57 | 128 | 1.00 | 1.00 |
| AC/CCc | 60 | 95 | 1.25 (0.78–2.00) | 1.24 (0.72–2.12) |
| IL-18 | ||||
| GG | 61 | 111 | 1.00 | 1.00 |
| GC/CCc | 56 | 105 | 0.85 (0.53–1.36) | 0.98 (0.56–1.69) |
| IL-6 | ||||
| GC/CC | 46 | 118 | 1.00 | 1.00 |
| GGc | 71 | 103 | 1.44 (0.89–2.34) | 1.42 (0.81–2.49) |
| IFNγ (SNP1) | ||||
| GG | 48 | 87 | 1.00 | 1.00 |
| GA/AAc | 66 | 122 | 1.04 (0.64–1.69) | 0.99 (0.57–1.73) |
| IFNγ (SNP2) | ||||
| GG/GC | 57 | 114 | 1.00 | 1.00 |
| CCc | 56 | 92 | 1.28 (0.79–2.06) | 1.20 (0.70–2.08) |
| Total low-activity Th1 genotypesd | ||||
| 0 | 15 | 37 | 1.00 | 1.00 |
| 1 | 36 | 83 | 1.01 (0.48–2.09) | 1.22 (0.53–2.84) |
| 2 | 44 | 68 | 1.39 (0.67–2.90) | 1.59 (0.69–3.66) |
| 3 | 19 | 22 | 1.30 (0.52–3.25) | 1.53 (0.53–4.39) |
| P for trend | 0.30 | 0.27 | ||
| Th2 genes | ||||
| IL-4 | ||||
| CT/TT | 47 | 77 | 1.00 | 1.00 |
| CCc | 71 | 147 | 1.03 (0.63–1.69) | 0.91 (0.51–1.61) |
| IL-10 | ||||
| GG/GA | 79 | 147 | 1.00 | 1.00 |
| AAc | 39 | 67 | 0.89 (0.53–1.48) | 0.80 (0.44–1.45) |
| Total low-activity Th2 genotypese | ||||
| 0 | 27 | 46 | 1.00 | 1.00 |
| 1 | 72 | 127 | 1.03 (0.57–1.85) | 0.89 (0.45–1.76) |
| 2 | 18 | 40 | 0.85 (0.40–1.82) | 0.64 (0.27–1.55) |
| P for trend | 0.70 | 0.34 | ||
ORs were calculated using logistic regression models, adjusting for age, gender and ethnicity (non-Hispanic white or Hispanic white/black).
ORs were further adjusted for level of education, cigarette smoking (never-/long-term ex-smokers, <20 or 20+ cigarettes/day of current/recent ex-smokers), number of alcoholic drinks per day (non-drinkers, <3 or ≥3), history of diabetes and hepatitis B/C serology (positive for hepatitis B surface antigen, antibodies to hepatitis B core antigen or antibodies to HCV).
Putative low-activity genotypes.
Summed across IL-6, IL-12 and IL-18 genotypes.
Summed across IL-4 and IL-10 genotypes.